This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer’s disease


de Oliveira, Fabricio Ferreira, Bertolucci, Paulo Henrique Ferreira, Chen, Elizabeth Suchi, Smith, Marilia de Arruda Cardoso


Journal of the Neurological Sciences, Volume: 336, No.: 1-2, Pages.: 103-108

Year of Publication



To evaluate correlations of pharmacological treatment with cognitive and behavioral symptoms in patients with dementia due to Alzheimer’s disease with low schooling, subjects were assessed for demographic features, neuropsychiatric symptoms, cognitive decline, functionality, caregiver burden, APOE haplotypes and pharmacological treatment. Among 217 patients, use of cholinesterase inhibitors with or without Memantine was associated with less neuropsychiatric symptoms, while anti-psychotics and/or anti-epileptic drugs were associated with lower instrumental functionality. Anti-psychotics were also associated with more neuropsychiatric symptoms in moderately impaired patients, possibly reflecting the greater need for such treatment when behavioral symptoms are present. Patients receiving more medications were usually younger, obese, married, with higher schooling and more neuropsychiatric symptoms. APOE4+ haplotypes were correlated with earlier dementia onset, but not with pharmacological treatment. Higher caregiver burden was associated with more psychotropic drugs. A trend was found for treatment with cholinesterase inhibitors and Memantine to be associated with longer lengths of dementia for moderately impaired but not for severely impaired patients, regardless of APOE haplotypes, translating into a synergistic effect among such medications for slowing cognitive decline but not for prolonging survival. Further longitudinal studies may be required to assess dose–response relationships regarding treatment with psychotropics for patients with dementia. (PsycINFO Database Record (c) 2014 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{de_Oliveira_2014, doi = {10.1016/j.jns.2013.10.015}, url = {}, year = 2014, month = {jan}, publisher = {Elsevier {BV}}, volume = {336}, number = {1-2}, pages = {103--108}, author = {Fabricio Ferreira de Oliveira and Paulo Henrique Ferreira Bertolucci and Elizabeth Suchi Chen and Marilia de Arruda Cardoso Smith}, title = {Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer{textquotesingle}s disease}, journal = {Journal of the Neurological Sciences} }


alzheimer’s disease, antiepileptic, cognitive disorders, cognitive impairment, dementia, drug therapy, drugs, memantine, neuropsychiatry

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

ADLs/IADLs, Carer Burden (instruments measuring burden), Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime, Antipsychotics and antidepressants, Other